Pharmacological Approach to Improve the Outcome of Social Cognition Training
2013年3月27日 更新者：Stephen R Marder, MD、VA Greater Los Angeles Healthcare System
This study will evaluate whether oxytocin will facilitate the learning of social cognitive skills in schizophrenia patients who receive 12 sessions of Social Cognitive Skills Training (SCST).
The primary hypothesis is that schizophrenia subjects who are treated with oxytocin will demonstrate greater improvements in a summary measure of social cognition than subjects treated with placebo over the course of SCST.
調査の概要
詳細な説明
Individuals with schizophrenia often have serious deficits in their abilities to perceive and interpret socially relevant information. These deficits in social cognition can lead to misunderstanding the intentions of others and failing to interpret social signals that are important for successful social interactions. The relationship between social cognition and functioning has led our group to develop a research agenda that includes understanding the neural underpinnings of social cognitive deficits, measuring these impairments using brain-based biomarkers and clinical assessments, and enhancing our Social Cognitive Skills Training program to improve social cognition and promote recovery.
Oxytocin, which is a hormone and neurotransmitter, is believed to impact social cognition through increased orienting toward and attending to socially salient visual features. There is also evidence that oxytocinergic signaling is impaired in schizophrenia. With this research, we hope to learn whether administration of oxytocin will improve different aspects of social cognition by examining the effects of oxytocin versus placebo administered intranasally before each of 12 sessions of a social cognitive skills training program on measures of independent living, work and social functioning.
研究の種類
介入
入学 (実際)
27
段階
- フェーズ 1
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90073
- West Los Angeles VA Medical Center
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
18年～55年 (大人)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
男
説明
Inclusion Criteria:
- Diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders 4th edition
- Stable on an antipsychotic medication
- No change in antipsychotic dose of >10% during the past 3 months
Exclusion Criteria:
- Unable to provide informed consent
- History of epilepsy
- Active medical conditions that would make the study unsafe
- History of serious head injury
- History of hyponatremia
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ：Placebo+Social Cognitive Skills Training
The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation.
These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice.
The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks.
The treatment groups will include individuals who are assigned to placebo.
Each training session will last for about 90 minutes (1 hour training and 30 minutes between placebo administration and start of training).
|
Placebo, matched to Oxytocin, intranasal inhalation
The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation.
These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice.
The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks.
Each training session will last for about 90 minutes (1 hour training and 30 minutes between drug administration and start of training).
|
|
実験的：Oxytocin+Social Cognitive Skill Training
The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation.
These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice.
The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks.
The treatment groups will include individuals who are assigned to oxytocin.
Each training session will last 90 minutes (1 hour training and 30 minutes between oxytocin administration and start of training).
|
The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation.
These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice.
The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks.
Each training session will last for about 90 minutes (1 hour training and 30 minutes between drug administration and start of training).
Oxytocin 40 IU, intranasal inhalation
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Composite Social Cognition Score
時間枠：Baseline, 6 weeks, and 10 weeks
|
We will assess emotion management, emotion perception, social context processing/social perception, theory of mind, attributional bias, and empathic accuracy.
The primary summary measure for each test will be mean-centered and standardized to create a Z-score that will be averaged to create a single composite score for social cognition, serving as the primary outcome measure.
Parallel follow-up analyses will be conducted on individual components to determine which measures are most affected by treatment.
Similar secondary analyses will be employed for the event related potential (ERP) and basic cognition measures.
|
Baseline, 6 weeks, and 10 weeks
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
捜査官
- 主任研究者：Stephen R Marder, MD、Department of Veterans Affairs, University of California Los Angeles
出版物と役立つリンク
研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。
一般刊行物
- Feifel D, Macdonald K, Nguyen A, Cobb P, Warlan H, Galangue B, Minassian A, Becker O, Cooper J, Perry W, Lefebvre M, Gonzales J, Hadley A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry. 2010 Oct 1;68(7):678-80. doi: 10.1016/j.biopsych.2010.04.039. Epub 2010 Jul 7.
- Marder SR, Wirshing WC, Mintz J, McKenzie J, Johnston K, Eckman TA, Lebell M, Zimmerman K, Liberman RP. Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. Am J Psychiatry. 1996 Dec;153(12):1585-92. doi: 10.1176/ajp.153.12.1585.
- Horan WP, Kern RS, Tripp C, Hellemann G, Wynn JK, Bell M, Marder SR, Green MF. Efficacy and specificity of social cognitive skills training for outpatients with psychotic disorders. J Psychiatr Res. 2011 Aug;45(8):1113-22. doi: 10.1016/j.jpsychires.2011.01.015. Epub 2011 Mar 4.
- Heinrichs M, von Dawans B, Domes G. Oxytocin, vasopressin, and human social behavior. Front Neuroendocrinol. 2009 Oct;30(4):548-557. doi: 10.1016/j.yfrne.2009.05.005. Epub 2009 Jun 6.
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始
2012年1月1日
一次修了 (実際)
2013年2月1日
研究の完了 (実際)
2013年2月1日
試験登録日
最初に提出
2012年1月19日
QC基準を満たした最初の提出物
2012年1月19日
最初の投稿 (見積もり)
2012年1月25日
学習記録の更新
投稿された最後の更新 (見積もり)
2013年3月29日
QC基準を満たした最後の更新が送信されました
2013年3月27日
最終確認日
2013年3月1日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。